NCT06891183

Brief Summary

Lung cancer has a high incidence globally, with Egypt having it as the third most common and most lethal cancer, affecting 16.9% of males and 3.8% of females. While surgery is the preferred treatment for stage 1 non-small cell lung cancer due to positive outcomes, it carries significant risks due to patient comorbidities. Non-invasive treatments like radio frequency ablation (RFA) and microwave ablation (MWA) are alternatives for those unable to undergo surgery. These techniques use energy to destroy tumor tissue with minimal invasiveness and can be guided by computed tomography to ensure accurate ablation.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable lung-cancer

Timeline
Completed

Started May 2023

Typical duration for not_applicable lung-cancer

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2023

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

September 12, 2024

Completed
6 months until next milestone

First Posted

Study publicly available on registry

March 24, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

March 24, 2025

Status Verified

March 1, 2025

Enrollment Period

3 years

First QC Date

September 12, 2024

Last Update Submit

March 17, 2025

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (1)

  • Accuracy and success

    Determination of tumor size in cm after thermal ablation in treatment of patients who are unfit for surgery or have tumors smaller than 5 cm or metastasis to the lung

    1 year

Study Arms (1)

Patients

EXPERIMENTAL

Thermal ablation of lung tumors

Radiation: Percutaneous thermal ablation of lung tumors

Interventions

Percutaneous thermal ablation of lung tumorsRADIATION

Percutaneous radiofrequency ablation

Patients

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • lung cancer smaller than 5 cm
  • metastasis to the lung
  • patients with lung cancer and multiple comorbidities who are unfit for surgery

You may not qualify if:

  • lung cancer larger than 5 cm
  • lung cancer stage II or more
  • patients who cannot tolerate CT guided needle placement for thermal ablation of lung tumors

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of medicine

Asyut, 71511, Egypt

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Abdulrahman F Ali

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Abdulrahman F Ali, Bachelor

CONTACT

1200742058Abdulrahman_farid@hotmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident

Study Record Dates

First Submitted

September 12, 2024

First Posted

March 24, 2025

Study Start

May 1, 2023

Primary Completion

May 1, 2026

Study Completion

May 1, 2026

Last Updated

March 24, 2025

Record last verified: 2025-03

Locations

EG(1)